Pipeline

Kali Smart Dropper

Enhancing Eye Drop Adherence with Innovative Technology

Applying and tracking eye drop medication can be challenging, but the Kali Smart Dropper aims to change that. This smart eye dropper assistant will help boost adherence by reminding patients to take their drops, confirming they were applied correctly, and assisting with data collection and reporting.

The Kali Smart Dropper* will be a lightweight, portable,device designed to attach to an eye drop bottle. As a connected smart eye dropper, it will provide drop instillation assistance and real-time tracking of successful drop use.

Features of the Kali Smart Dropper* will include:

• Guidance feedback during drop application
• Detection of successful drop installation
• Adherence tracking and reminders via our mobile app
• Integrates into our Twenty/Twenty Vision Suite for comprehensive glaucoma management

*Note: These products in development have not been evaluated by FDA, and are not available for sale in the United States.

Viscous Microdose Delivery

Simplifying Eye Drop Instillation

Applying eye drops correctly can be challenging due to aiming difficulties, blinking or flinching and dexterity issues

Our aim is to make eye drop application easier, while reducing waste. This innovative device automatically releases a microdose of the selected eye drop onto the ocular surface (not the eyelids) using a unique LED aiming technique, triggered right after the user blinks!

This product will come with interchangeable cartridges of ophthalmic eye drops, starting with lubricating artificial tears to help manage dry eye symptoms.

Key features will include:

• Horizontal eye drop delivery
• LED-guided aiming for precise drop placement
• Automatic blink delivery and a manual delivery option
• Connectivity with our mobile app for eye drop and symptom tracking, as well as adherence reminders

*Note: These products in development have not been evaluated by FDA, and are not available for sale in the United States.

Drug Dispensing Contact Lens

Simplifying Therapy Adherence for Glaucoma

Managing glaucoma can be challenging, especially when it comes to medication adherence at home.

Our solution is a programmable drug dispensing contact lens designed to improve compliance of vision-saving glaucoma medications.

• Controls timing and dose of drug delivery
• Improves medication compliance
• Reduces eye drop intolerance by minimizing dose

*Note: These products in development have not been evaluated by FDA, and are not available for sale in the United States.

Closed-loop Glaucoma Pump

Revolutionizing Glaucoma Treatment

Glaucoma drainage devices often fail in a significant number of patients, with nearly 50% of implants becoming ineffective after just one year.

Our device is a closed-loop glaucoma pump designed to revolutionize glaucoma treatment. It is the first active glaucoma drainage device that will dynamically regulate intraocular pressure for more consistent eye pressure management in patients with glaucoma.

Expected Benefits:

• Overcomes common reasons for failure of glaucoma drainage implants
• Dynamic IOP control in both the diurnal cycle and over time
• Anti-immunogenic material to reduce post-implantation fibrosis

*Note: These products in development have not been evaluated by FDA, and are not available for sale in the United States.

Tonoptic

Continuous IOP Monitoring: A Breakthrough in Glaucoma Management

Eye pressure tends to be most elevated in the early morning when patients are asleep. These unmonitored early morning spikes can negatively affect glaucoma management. While home monitoring devices are helpful, their effectiveness depends on users taking the initiative to take a measurement.

Tonoptic is a minimally invasive, implantable device created to offer continuous eye pressure monitoring, enabling personalized and precise glaucoma management.

Utilizing advanced microelectronics, Tonoptic will feature an optically integrated MEMS pressure sensor and a handheld reader. The device will integrate with the Twenty/Twenty Vision Suite for comprehensive glaucoma management.

Tonoptic is set to revolutionize glaucoma care.

*Note: These products in development have not been evaluated by FDA, and are not available for sale in the United States.

Meibomian Gland Dysfunction

Transforming MGD Therapy: Combining Heat and Massage in One Simple Solution

Dry eye caused by meibomian gland dysfunction (MGD) can be painful and costly to manage, with current treatments presenting various challenges.

At-home therapies like compress masks often fall short and require extra time and maintenance, while in-office procedures are expensive, complex, and lengthy.

Our solution will combine the typical in-office procedure into a single device, applying therapeutic levels of heat to the eyelids and delivering targeted massage to the entire lid in under 3 minutes, streamlining MGD treatment for patients.

*Note: These products in development have not been evaluated by FDA, and are not available for sale in the United States.

VitreoDx

Personalizing IVI therapy

Intravitreal injection (IVI) therapy is widely used for nvAMD and DR, but over 10% of patients don’t adquently respond and undergo multiple cycles before changing therapy, risking vision loss. Biomarkers could help physicians personalize treatment for individual patients.

Our advanced intravitreal injection technology allows for tissue sampling and therapeutic injection in one step, analyzing vitreous biomarkers to determine the best treatment options for macular degeneration patients.

Anticipated Benefits:

• Personalized therapy based on biomarkers
• Reduced risk of IVI complications
• Eliminates current “trial and error” approach for macular degeneration therapy

*Note: These products in development have not been evaluated by FDA, and are not available for sale in the United States.

Aqueous Deficiency

Natural Dry Eye Relief

Dry-eye disease can be painful, expensive, and challenging to manage, significantly impacting patients’ quality of life and comfort.

Our innovative solution is an ocular wearable device, similar to a contact lens, but discreetly located in the inferior fornix (hidden by the lower eyelid). This unique device uses low-level electrical currents to stimulate natural tear production for those with dry eye, all while being encased in a comfortable hydrogel material.

• Natural, preservative free dry eye therapy
• Wireless, on-demand therapy initiation for all day relief
• Integrates into Twenty/Twenty Vision Suite for comprehensive dry eye management

*Note: These products in development have not been evaluated by FDA, and are not available for sale in the United States.

Neuroprotection

Fighting Blindness with Groundbreaking Neuroprotection Lenses

Retinitis Pigmentosa (RP) is a rare inherited disease that often results in blindness and currently, no definitive treatment is available.

Our Neuroprotection Lens offers hope by aiming to slow or halt retinal degeneration in RP patients and other neurodegenerative eye diseases through transcorneal stimulation.

This product will utilize transcorneal stimulation to slow or halt retinal degeneration in patients with RP and other degenerative eye diseases.

• Clinical data supports neuro-protective and vision enhancing efficacy
• Well-tolerated, non-invasive therapy

Tackling the challenges of degenerative eye disease with our revolutionary Neuroprotection Lens.

*Note: These products in development have not been evaluated by FDA, and are not available for sale in the United States.

Myopia Wearables

Combating Myopia with Violet Light Technology

Myopia is a growing pandemic with highest rates in Asia. Current solutions are expensive, time consuming, increase risk of infection or have potential for side effects (Ortho-K, soft Multifocal contact lenses, Atropine).

Myopia wearable is a pair of compact optoelectronic components that can be semipermanently attached to a child’s glasses of choice to emit violet light that has been shown to slow myopia progression. The devices will provide 3 hours of violet light exposure each day at an intensity approximately equivalent to normal average outdoor exposure to prevent or slow myopia progression.

Features:

• 3 hours of VL exposure equivalent to outdoor exposure
• Attachable to any pair of standard children’s glasses
• Minimizes increase risk of infection or systemic side effects associated with other therapies

*Note: These products in development have not been evaluated by FDA, and are not available for sale in the United States.

Kali Smart Dropper

Enhancing Eye Drop Adherence with Innovative Technology

Applying and tracking eye drop medication can be challenging, but the Kali Smart Dropper aims to change that. This smart eye dropper assistant will help boost adherence by reminding patients to take their drops, confirming they were applied correctly, and assisting with data collection and reporting.

The Kali Smart Dropper* will be a lightweight, portable,device designed to attach to an eye drop bottle. As a connected smart eye dropper, it will provide drop instillation assistance and real-time tracking of successful drop use.

Features of the Kali Smart Dropper* will include:

• Guidance feedback during drop application
• Detection of successful drop installation
• Adherence tracking and reminders via our mobile app
• Integrates into our Twenty/Twenty Vision Suite for comprehensive glaucoma management

*Note: These products in development have not been evaluated by FDA, and are not available for sale in the United States.

Tonoptic

Continuous IOP Monitoring: A Breakthrough in Glaucoma Management

Eye pressure tends to be most elevated in the early morning when patients are asleep. These unmonitored early morning spikes can negatively affect glaucoma management. While home monitoring devices are helpful, their effectiveness depends on users taking the initiative to take a measurement.

Tonoptic is a minimally invasive, implantable device created to offer continuous eye pressure monitoring, enabling personalized and precise glaucoma management.

Utilizing advanced microelectronics, Tonoptic will feature an optically integrated MEMS pressure sensor and a handheld reader. The device will integrate with the Twenty/Twenty Vision Suite for comprehensive glaucoma management.

Tonoptic is set to revolutionize glaucoma care.

*Note: These products in development have not been evaluated by FDA, and are not available for sale in the United States.

Viscous Microdose Delivery

Simplifying Eye Drop Instillation

Applying eye drops correctly can be challenging due to aiming difficulties, blinking or flinching and dexterity issues

Our aim is to make eye drop application easier, while reducing waste. This innovative device automatically releases a microdose of the selected eye drop onto the ocular surface (not the eyelids) using a unique LED aiming technique, triggered right after the user blinks!

This product will come with interchangeable cartridges of ophthalmic eye drops, starting with lubricating artificial tears to help manage dry eye symptoms.

Key features will include:

• Horizontal eye drop delivery
• LED-guided aiming for precise drop placement
• Automatic blink delivery and a manual delivery option
• Connectivity with our mobile app for eye drop and symptom tracking, as well as adherence reminders

*Note: These products in development have not been evaluated by FDA, and are not available for sale in the United States.

Meibomian Gland Dysfunction

Transforming MGD Therapy: Combining Heat and Massage in One Simple Solution

Dry eye caused by meibomian gland dysfunction (MGD) can be painful and costly to manage, with current treatments presenting various challenges.

At-home therapies like compress masks often fall short and require extra time and maintenance, while in-office procedures are expensive, complex, and lengthy.

Our solution will combine the typical in-office procedure into a single device, applying therapeutic levels of heat to the eyelids and delivering targeted massage to the entire lid in under 3 minutes, streamlining MGD treatment for patients.

*Note: These products in development have not been evaluated by FDA, and are not available for sale in the United States.

Aqueous Deficiency

Natural Dry Eye Relief

Dry-eye disease can be painful, expensive, and challenging to manage, significantly impacting patients’ quality of life and comfort.

Our innovative solution is an ocular wearable device, similar to a contact lens, but discreetly located in the inferior fornix (hidden by the lower eyelid). This unique device uses low-level electrical currents to stimulate natural tear production for those with dry eye, all while being encased in a comfortable hydrogel material.

• Natural, preservative free dry eye therapy
• Wireless, on-demand therapy initiation for all day relief
• Integrates into Twenty/Twenty Vision Suite for comprehensive dry eye management

*Note: These products in development have not been evaluated by FDA, and are not available for sale in the United States.

Drug Dispensing Contact Lens

Simplifying Therapy Adherence for Glaucoma

Managing glaucoma can be challenging, especially when it comes to medication adherence at home.

Our solution is a programmable drug dispensing contact lens designed to improve compliance of vision-saving glaucoma medications.

• Controls timing and dose of drug delivery
• Improves medication compliance
• Reduces eye drop intolerance by minimizing dose

*Note: These products in development have not been evaluated by FDA, and are not available for sale in the United States.

Neuroprotection

Fighting Blindness with Groundbreaking Neuroprotection Lenses

Retinitis Pigmentosa (RP) is a rare inherited disease that often results in blindness and currently, no definitive treatment is available.

Our Neuroprotection Lens offers hope by aiming to slow or halt retinal degeneration in RP patients and other neurodegenerative eye diseases through transcorneal stimulation.

This product will utilize transcorneal stimulation to slow or halt retinal degeneration in patients with RP and other degenerative eye diseases.

• Clinical data supports neuro-protective and vision enhancing efficacy
• Well-tolerated, non-invasive therapy

Tackling the challenges of degenerative eye disease with our revolutionary Neuroprotection Lens.

*Note: These products in development have not been evaluated by FDA, and are not available for sale in the United States.

Closed-loop Glaucoma Pump

Revolutionizing Glaucoma Treatment

Glaucoma drainage devices often fail in a significant number of patients, with nearly 50% of implants becoming ineffective after just one year.

Our device is a closed-loop glaucoma pump designed to revolutionize glaucoma treatment. It is the first active glaucoma drainage device that will dynamically regulate intraocular pressure for more consistent eye pressure management in patients with glaucoma.

Expected Benefits:

• Overcomes common reasons for failure of glaucoma drainage implants
• Dynamic IOP control in both the diurnal cycle and over time
• Anti-immunogenic material to reduce post-implantation fibrosis

*Note: These products in development have not been evaluated by FDA, and are not available for sale in the United States.

VitreoDx

Personalizing IVI therapy

Intravitreal injection (IVI) therapy is widely used for nvAMD and DR, but over 10% of patients don’t adquently respond and undergo multiple cycles before changing therapy, risking vision loss. Biomarkers could help physicians personalize treatment for individual patients.

Our advanced intravitreal injection technology allows for tissue sampling and therapeutic injection in one step, analyzing vitreous biomarkers to determine the best treatment options for macular degeneration patients.

Anticipated Benefits:

• Personalized therapy based on biomarkers
• Reduced risk of IVI complications
• Eliminates current “trial and error” approach for macular degeneration therapy

*Note: These products in development have not been evaluated by FDA, and are not available for sale in the United States.

Myopia Wearables

Combating Myopia with Violet Light Technology

Myopia is a growing pandemic with highest rates in Asia. Current solutions are expensive, time consuming, increase risk of infection or have potential for side effects (Ortho-K, soft Multifocal contact lenses, Atropine).

Myopia wearable is a pair of compact optoelectronic components that can be semipermanently attached to a child’s glasses of choice to emit violet light that has been shown to slow myopia progression. The devices will provide 3 hours of violet light exposure each day at an intensity approximately equivalent to normal average outdoor exposure to prevent or slow myopia progression.

Features:

• 3 hours of VL exposure equivalent to outdoor exposure
• Attachable to any pair of standard children’s glasses
• Minimizes increase risk of infection or systemic side effects associated with other therapies

*Note: These products in development have not been evaluated by FDA, and are not available for sale in the United States.